Fraxinus velutina pollen allergens (Fra v allergens)

Fraxinus velutina pollen allergens are a group of proteins derived from the pollen of the Velvet Ash (also known as Arizona Ash), which are significant triggers for seasonal respiratory allergies in arid and semi-arid regions. These allergens, such as the major allergen Fra v 1, belong to the Oleaceae family and exhibit high cross-reactivity with allergens from other members of the family, including olive (Olea europaea) and common ash (Fraxinus excelsior). Upon inhalation, these proteins cross-link allergen-specific IgE on the surface of mast cells and basophils in sensitized individuals, leading to the release of inflammatory mediators like histamine and leukotrienes. This process results in clinical symptoms of allergic rhinitis, conjunctivitis, and bronchial asthma. In a therapeutic context, these allergens are the primary components of allergen-specific immunotherapy (AIT) formulations designed to desensitize patients and modify the underlying disease course. Additionally, they serve as targets for pharmacological interventions aimed at neutralizing IgE or dampening the Th2-driven inflammatory response.

Other names

Velvet ash pollen allergensArizona ash pollen allergensFra v 1Fra v 2Fra v 3

Allergen immunotherapy (AIT) involves the repeated administration of specific allergen extracts to induce immunological tolerance, shifting the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated regulatory profile. Monoclonal antibodies like omalizumab bind to circulating IgE, preventing it from attaching to the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade triggered by these allergens.